Stroke with polyvascular atherothrombotic disease

Atherosclerosis

Volumn 208, Issue 2, 2010, Pages 587-592

  Blanco, Miguel ^a   Sobrino, Tomás ^a   Montaner, Joan ^b   Medrano, Vicente ^c   Jiménez, Carmen ^d   Masjuán, Jaime ^e   Gómez Escalonilla, Carlos ^f   de Luis, Pilar ^g   Arboix, Adriá ^h   Castillo, José ^a  

^a Instituto de Salud Carlos III   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL GENERAL DE ELDA   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

Author keywords

Atherosclerosis progression; Inflammation; Ischemic stroke; Polyvascular atherothrombotic disease

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; FIBRONECTIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; LIMB AMPUTATION; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; THROMBOSIS;

AGED; ANGINA PECTORIS; ANTICOAGULANTS; ARTERIES; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; STROKE; THROMBOSIS;

EID: 74749104436     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.07.041     Document Type: Article

References (30)

1. Jemal A., Ward E., Hao Y., and Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 294 (2005) 1255-1259
2. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349 (1997) 1498-1504
3. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1324
4. Steg P.G., Bhatt D.L., Wilson P.W., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007) 1197-1206
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
6. Castillo J., Álvarez-Sabín J., Martínez-Vila E., Montaner E., Sobrino T., Vivancos J., and on behalf of the MÍTICO Study Investigators. Inflammation markers and prediction of poststroke vascular disease recurrence; The MITICO Study. J Neurol 256 (2009) 217-224
7. Comité ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología; Guía para el diagnóstico y tratamiento del ictus; Barcelona; 2004.
8. Aronow W.S., and Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women ≥62 years of age. Am J Cardiol 74 (1994) 64-65
9. Kannel W.B. Overview of atherosclerosis. Clin Ther 20 Suppl. B (1998) B2-B17
10. Rothwell P.M., Villagra R., Gibson R., Donders R.C., and Warlow C.P. Evidence of a chronic systemic cause of instability of atherosclerotic plaques. Lancet 355 (2000) 19-24
11. Mukherjee D., Eagle K.A., Kline-Rogers E., et al. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol 100 (2007) 1-6
12. Silva J.A., and White C.J. Plaque instability in peripheral vessels. Prog Cardiovasc Dis 44 (2002) 429-436
13. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American symptomatic carotid endarterectomy trial collaborators. N Engl J Med 325 (1991) 445-453
14. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351 (1998) 1379-1387
15. Hobson R.Wn., Weiss D.G., Fields W.S., et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The veterans affairs cooperative study group. N Engl J Med 328 (1993) 221-227
16. Carotid surgery versus medical therapy in asymptomatic carotid stenosis. The CASANOVA Study Group. Stroke 22 (1991) 1229-1235
17. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
18. Schillinger M., Exner M., Mlekusch W., et al. Inflammation and carotid artery-risk for atherosclerosis study (ICARAS). Circulation 111 (2005) 2203-2209
19. Lijnen H.R. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 33 (2003) 275-281
20. Galderisi M., and de Divitiis O. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 51 (2008) 523-531
21. Rodriguez J.A., Orbe J., Martinez de Lizarrondo S., et al. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front Biosci 13 (2008) 2916-2921
22. Fiotti N., Altamura N., Fisicaro M., et al. MMP-9 microsatellite polymorphism: association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques. Atherosclerosis 182 (2005) 287-292
23. Babaev V.R., Porro F., Linton M.F., Fazio S., Baralle F.E., and Muro A.F. Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis 197 (2008) 534-540
24. Song K.S., Kim H.K., Shim W., and Jee S.H. Plasma fibronectin levels in ischemic heart disease. Atherosclerosis 154 (2001) 449-453
25. van der Graaf C., Kullberg B.J., Joosten L., et al. Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 30 (2005) 264-268
26. Cipollone F., Fazia M., Iezzi A., et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 109 (2004) 1482-1488
27. Khan Q., and Mehta J.L. Relevance of platelet-independent effects of aspirin to its salutary effect in atherosclerosis-related events. J Atheroscler Thromb 12 (2005) 185-190
28. Hachicha M., Pouliot M., Petasis N.A., and Serhan C.N. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med 189 (1999) 1923-1930
29. Weber M.S., Prod'homme T., Steinman L., and Zamvil S.S. Drug insight: using statins to treat neuroinflammatory disease. Nat Clin Pract Neurol 1 (2005) 106-112
30. Martin-Ventura J.L., Blanco-Colio L.M., Gomez-Hernandez A., et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 36 (2005) 1796-1800